Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of autologous RAK cells to prevent high-risk recurrence after curative resection of hepatocellular carcinoma
CTR20231914Phase 2Active
- Sponsor
- Puhua Saier
- Start
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of RAK cells in hepatocellular carcinoma (HCC), sponsored by Puhua Saier. Started Oct 2023; status: active.
02
Drugs
RAK cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20231914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231914.